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2 
ABSTRACT 27 
Favipiravir (T-705) is a broad-spectrum antiviral agent that has been approved in Japan 28 
for treatment of influenza virus infections. T-705 also inhibits the replication of various 29 
RNA viruses including chikungunya virus (CHIKV). We demonstrated earlier that the 30 
K291R mutation in the F1 motif of the RNA-dependent RNA polymerase (RdRp) of 31 
CHIKV is responsible for low-level resistance to T-705. Interestingly, this lysine is highly 32 
conserved in the RdRp of positive-sense single-stranded RNA [+ssRNA] viruses. To ob-33 
tain insights into the unique broad-spectrum antiviral activity of T-705, we explored the 34 
role of this lysine using another +ssRNA virus, namely Coxsackievirus B3 (CVB3). Intro-35 
duction of the corresponding K-to-R substitution in the CVB3 RdRp (K159R) resulted in 36 
a non-viable virus. Replication competence of the K159R variant was restored by spon-37 
taneous acquisition of an A239G substitution in the RdRp. A mutagenesis analysis at 38 
position K159 identified K159M as the only other viable variant, which had also ac-39 
quired the A239G substitution. The K159 substitutions markedly decreased the proces-40 
sivity of the purified viral RdRp, which was restored by introduction of the A239G muta-41 
tion. The K159R-A239G and K159M-A239G variants proved, surprisingly, more suscep-42 
tible to T-705 than the wild-type virus and exhibited lower fidelity in polymerase as-43 
says. Furthermore, the K159R-A239G variant was found to be highly attenuated in mice. 44 
We thus demonstrate that the conserved lysine in the F1 motif of the RdRp of +ssRNA 45 
viruses is involved in the broad-spectrum antiviral activity of T-705 and that it is a key 46 
amino acid for the proper functioning of the enzyme.  47 
Key words 48 
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3 
IMPORTANCE 50 
In this study, we report the key role of a highly conserved lysine residue of the viral pol-51 
ymerase in the broad-spectrum antiviral activity of favipiravir (T-705) against positive 52 
single-stranded RNA viruses. Substitutions of this conserved lysine have a major nega-53 
tive impact on the functionality of the RdRp. Furthermore we show that this lysine is 54 
involved in the fidelity of the RdRp and that the RdRp fidelity influences the sensitivity 55 
of the virus for the antiviral efficacy of T-705. Consequently, these results provide in-56 
sights into the mechanism of the antiviral activity of T-705 and may lay the basis for the 57 
design of novel chemical scaffolds that may be endowed with a more potent broad-58 




Favipiravir (T-705) is a broad-spectrum antiviral agent that has been approved in Japan 62 
for the treatment of influenza virus infections (1). T-705 has also been reported to inhib-63 
it, in vitro and in animal models, the replication of different RNA viruses, including no-64 
rovirus (2), flaviviruses (3) and hantaviruses (4). The compound also showed a potential 65 
beneficial effect in the treatment of Ebola virus infected patients in Western Africa dur-66 
ing the 2014/2015 outbreak (5). 67 
In the cell, T-705 behaves as a purine analogue and is converted into its ribofuranosyl 5’-68 
triphosphate metabolite (T-705-RTP), after which it can be incorporated in the growing 69 
RNA strand as has been shown with the influenza virus RNA-dependent RNA polymer-70 
ase (RdRp) (1). However, the precise molecular mechanism behind its broad-spectrum 71 
antiviral activity has yet to be fully elucidated. Some studies suggest that T-705 inhibits 72 
viral RNA synthesis by chain termination of the nascent viral RNA strand (6), while oth-73 
er reports support the induction of lethal mutagenesis (7, 8). 74 
In a previous study from our laboratory, T-705 and its defluorinated analog, T-1105 75 
were shown to inhibit the in vitro replication of chikungunya virus (CHIKV) (9). Treat-76 
ment of CHIKV-infected AG129 mice with T-705 protected these from severe neurologi-77 
cal disease and reduced the mortality rate (9). Low-level T-705-resistant CHIKV variants 78 
were selected in vitro and were shown to have acquired the K291R mutation in motif F1 79 
of the RdRp and a reverse-engineering study corroborated the link between mutant 80 
genotype and compound-resistant phenotype (9). Motif F of the RdRp of single-81 
stranded, positive-sense (+ss) RNA viruses has been reported to play an important role 82 
in NTP binding during viral RNA synthesis (10). It was also demonstrated that motif F1 83 
of dengue virus is involved in promoter-dependent initiation of RNA synthesis (11). In 84 
addition, some residues of motif F of Japanese encephalitis virus were shown to be in-85 
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volved in GTP recognition (12). Interestingly, the lysine residue of motif F1 which was 86 
mutated in the T-705-resistant CHIKV variants, is highly conserved amongst +ssRNA 87 
viruses, a group to which many neglected and emerging viruses belong (Figure 1). The 88 
exact role of this lysine in viral RdRp activity remains unclear. Given the need for broad-89 
spectrum antivirals, it is thus of great importance to understand how T-705 precisely 90 
interacts with the RdRp of RNA viruses. Such information may potentially provide in-91 
sight into how more potent broad-spectrum +ssRNA virus inhibitors can be developed. 92 
We here explored whether the conserved lysine in the F1 motif of the viral RdRp is in-93 
volved in the broad-spectrum antiviral activity of T-705. To this end, we used the Cox-94 
sackievirus B3 (CVB3), another +ssRNA virus that is sensitive to T-705 and for which we 95 
have the necessary reverse-genetics tools and enzymatic assays available, as the model 96 
virus in this study. Using CVB3, we demonstrate for the first time that this highly con-97 
served lysine residue plays a key role in RdRp functionality and fidelity and that a vari-98 
ant of this residue exhibits a highly attenuated phenotype in mice. We next succeeded to 99 
elucidate the mechanism of resistance against T-705, thereby demonstrating the role of 100 
RdRp fidelity in sensitivity to the antiviral agent.  101 
  102 
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RESULTS 103 
Viable CVB3-K159 mutants acquired the A239G mutation in the RdRp 104 
Low-level T-705-resistant CHIKV variants were reported to have the K291R mutation in 105 
motif F1 of the RdRp (9). Because this lysine residue is highly conserved in the RdRp of 106 
+ssRNA viruses (Figure 1), we introduced the K-to-R mutation at the corresponding 107 
position in motif F1 of the CVB3 RdRp (K159R) to assess the sensitivity of this mutant to 108 
the antiviral effect of T-705 (Figure 2). Initially, no infectious virus could be recovered. 109 
However, during the second transfection round, virus-induced CPE was observed and 110 
infectious virus was recovered. Sequencing of this virus sample revealed that, in addi-111 
tion to the engineered K159R, it had also acquired the Alanine to glycine substitution at 112 
position 239 in motif A of the RdRp (Figure 2). Interestingly, the single A239G mutant 113 
has been reported to be a low fidelity RdRp CVB3 variant (13). 114 
To explore the importance of the lysine at position 159 in the CVB3 RdRp, a full set of 115 
mutations was engineered, each coding for another amino acid residue at this position. 116 
From nine of these infectious clones, no virus could be recovered from cell culture after 117 
two transfection rounds and no RNA replication could be detected, requiring them to be 118 
labeled as ‘not viable’. Another eight mutants reverted back to WT (Table 1). Only trans-119 
fection with the K159M clone allowed recovering infectious virus with a mutation at 120 
position 159, however only after it had acquired the A239G substitution (Table 1). The 121 
low fidelity RdRp variant (A239G) (13) and a high fidelity RdRp variant (A372V) (14) 122 
were also generated to be used as controls in the next experiments. 123 
K159 mutations in the CVB3 RdRp gene affect polymerase competence  124 
An enzymatic study was performed to determine how the K159 mutations affect RdRp 125 
activity. The in vitro polymerase assays were performed with purified CVB3 RdRp and a 126 
homo-polymeric primer-template substrate (Figure 3A) allowing [α-32P]-UMP incor-127 
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poration into RNA after 2, 5 and 10 min. Relative to WT polymerase, the single K159R 128 
and K159M variants showed significant differences of overall 100- and 15-fold decrease 129 
in polymerase activity, respectively (Figure 3B/C). Interestingly, introduction of the 130 
A239G mutation partially restored the overall polymerase activity of both K159 mu-131 
tants (Figure 3B/C). Based on structural analysis of the picornavirus CVB3 (PDB code 132 
3CDW), the Arg159 has a long side-chain compared to Lys159, which narrows the access 133 
of the incoming nucleotides and impedes correct positioning at the active site of the 134 
RdRp (Figure 4B/E). This may explain the lower efficiency noted in polymerase activity 135 
assays. In the case of Met159, it is suggested that the nitrogen group of the original ly-136 
sine residue has a main role in the binding and positioning of the incoming nucleotide 137 
and its substitution by a methyl group in methionine may therefore affect directly the 138 
NTP recognition and in turn NTP-positioning and catalysis. As shown in (Figure 4A/D), 139 
the residues Lys159 and Ala239 are spatially close in the channel of the incoming NTP. 140 
This channel becomes narrow when the Lys159 is mutated thereby hindering the access 141 
of the incoming NTP to the RdRp active site (Figure 4B/E). In order to maintain virus 142 
viability, the compensatory mutation A239G, with its absence of side-chain, appears to 143 
restore the open conformation of the NTP channel (Figure 4C/F).These data are in 144 
agreement with the fact that no viable single mutant viruses could be recovered after 145 
transfection in cell culture, and that the A239G mutation was spontaneously acquired by 146 
the K159R and K159M mutants to restore their ability to replicate in vitro. 147 
The K159R/M mutations result in an unfavorable phenotype 148 
The genetic stability of the amino acid substitutions of the K159R-A239G and K159M-149 
A239G mutants was studied during passaging in HeLa Rh cells. Already after three pas-150 
sages, both K159 mutants had reverted back to the WT lysine. The adaptive mutation at 151 
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position 239 appeared to be genetically stable, with or without the substitutions at posi-152 
tion 159 (Table 2). 153 
Plaque phenotyping of the reverse-engineered K159 mutants before passaging revealed 154 
that the plaque size of the K159M-A239G variant was comparable to that of WT, where-155 
as for the K159R-A239G variant, two populations with different plaque size were ob-156 
served (Figure 5A). Despite numerous attempts, it was not possible to obtain a pure 157 
small-plaque variant. In parallel, the in vitro growth kinetics of all variants were deter-158 
mined in Vero A cells by plaque assay. The A239G and K159R-A239G variants had slight-159 
ly slower growth kinetics compared to WT virus, whereas the K159M-A239G mutant 160 
replicated approximately as efficiently as WT (Figure 5B).  161 
CVB3-K159 mutants are more susceptible to the antiviral effect of T-705 162 
The susceptibility to the antiviral effect of T-705 (Figure 6) of WT virus as well as of 163 
RdRp mutants was quantified in a CPE reduction assay (Figure 5C). The K159R-A239G 164 
and K159M-A239G mutants proved to be respectively 3.4- and 2-fold more susceptible 165 
to the antiviral effect of T-705 than WT virus (Table 3). Also the single A239G mutant 166 
proved to be 2-fold more susceptible, whereas the high fidelity polymerase variant 167 
A372V was 2-fold less sensitive to T-705 than WT. The susceptibility of the K159 vari-168 
ants to the antiviral effect of ribavirin (which acts as a mutagenic agent and by depletion 169 
of GTP pools) (15) and rupintrivir (an inhibitor of the viral 3C protease) was not signifi-170 
cantly altered (Table 3, Figure 6). 171 
K159 mutations affect polymerase fidelity 172 
Because low and high fidelity variants of the RdRp (A239G and A372V) exhibited a dif-173 
ferent susceptibility to T-705, in vitro polymerase assays were performed to assess the 174 
effect of the K159 mutations on polymerase fidelity (Figure 7). In these enzymatic as-175 
says, insertion of the correct nucleotide (UTP) into RNA was challenged with increasing 176 
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concentrations of an incorrect (CTP) nucleotide. The low polymerase efficiency of single 177 
K159R and K159M variants technically precluded their use in fidelity analysis assays. 178 
The A239G variant was used as low fidelity control (13, 14). The RNA product formed 179 
was quantified and fit as a dose-response curve framing the incorrect nucleotide concen-180 
tration able to inhibit 50% of RNA product formation (reported as IC50). For WT, A239G, 181 
K159R-A239G and K159M-A239G, an IC50 of 2.9 ± 0.2 mM (Figure 7A/B), 2.5 ± 0.3 mM 182 
(Figure 7A/C), 1.7 ± 0.06 mM (Figure 7A/D) and 0.45 mM ± 0.04 (Figure 7A/E) were 183 
obtained when 3 μCi [α-32P]-UTP / 10μM unlabeled UTP was challenged with different 184 
concentrations of CTP, respectively. Altogether, these results indicate that the K159R-185 
A239G and K159M-A239G variants are respectively 1.7- and 6-fold more sensitive than 186 
the WT enzyme to the presence of an incorrect CTP nucleotide (Figure 7F). These re-187 
sults validate the hypothesis that the variants are indeed affected in their fidelity of nu-188 
cleotide selection or incorporation. Because loss of fidelity would also favor incorpora-189 
tion of T-705-RTP, these results are in agreement with the observation that the K159 190 
variants are more susceptible to the antiviral effect of this compound. 191 
T-705 acts as a mutagen during CVB3 replication 192 
To study whether T-705 acts as a mutagen on CVB3 replication, virus-infected HeLa Rh 193 
cells were treated with T-705 or ribavirin at a concentration equal to the EC50 of the cor-194 
responding compound (Table 3). This study was performed with the WT virus, the low 195 
fidelity A239G as well as the high fidelity A372V variant because, as demonstrated 196 
above, the K159 mutants easily revert back to WT, which would interfere with data 197 
analysis. On day 3 post-infection (p.i.), the supernatants were collected and subjected to 198 
deep sequencing to determine the mutation frequencies at each nucleotide position after 199 
drug treatment. As expected, the high fidelity A372V variant (Figure 8B, data repre-200 
senting open bars) has a significantly lower mean basal mutation frequency across its 201 
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genome [P<0.0001, paired two-tailed t-test, n=10,749] than the WT virus (Figure 8A, 202 
data representing open bars) whereas the low fidelity A239G variant showed the 203 
highest mean basal mutation frequency across its genome frequencies [P<0.0001, paired 204 
two-tailed t test, n=10,749] (Figure 8C, data representing open bars). Treatment with 205 
T-705 (Figure 8, light grey bars) and ribavirin (Figure 8, dark grey bars) resulted in a 206 
significantly higher basal mutation frequency for all CVB3 variants. The data demon-207 
strate that T-705 is a potent RNA mutagen for CVB3, especially for C->U and G->A transi-208 
tions, as has been previously described (16, 17). On the other hand, ribavirin increased 209 
the mutation frequency for all transition mutations. 210 
The K159R-A239G mutant is attenuated in vivo 211 
The fitness of CVB3 WT as well as the A239G, K159R-A239G and K159M-A239G mutants 212 
was studied in immunocompetent SJL mice. The A239G variant was included as a con-213 
trol for in vivo attenuation (13). Three days p.i., a time at which the highest virus titers 214 
are observed in the WT-infected mice, all mice were euthanized and serum, heart, spleen 215 
and pancreas were collected for RNA quantification (Figure 9). Mice infected with the 216 
A239G mutant had lower RNA levels in the serum and various organs than WT (Figure 217 
9A-D) as well as less infectious virus particles in the heart (Figure 9E), which is in 218 
agreement with previous reports. The K159R-A239G mutant was the most attenuated 219 
variant in this study inducing only low or undetectable levels of viral RNA in the heart 220 
(Figure 9B). Furthermore, no infectious virus particles were recovered from this organ 221 
(Figure 9E) in which CVB3 typically replicates to high titers. In contrast, the K159M-222 
A239G variant behaved comparable to WT (Figure 9A-E). Sequencing of the virus popu-223 
lation in serum samples of mice infected with the K159M-A239G variant revealed that 224 
this variant had reverted back to WT. 225 
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Discussion 226 
T-705 is a broad-spectrum antiviral compound that has been reported to inhibit the rep-227 
lication of a variety of RNA viruses, both in in vitro and in vivo models. In a previous 228 
study, CHIKV variants that are resistant to the antiviral activity of T-705 were selected 229 
and all of them were shown to have acquired the K291R mutation in motif F1 of the 230 
RdRp (9). Because this lysine residue is highly conserved in the RdRp of many different 231 
+ssRNA viruses, we hypothesized that this residue is essential for the polymerase activi-232 
ty of these viruses and that it is a key interactor with T-705-RTP. To challenge this hy-233 
pothesis, the K-to-R mutation was inserted at the equivalent position (K159R) in the 234 
infectious clone of CVB3. In parallel, two different resistance selection protocols (serial 235 
passaging and clonal selection) were used with the aim to select T-705-resistant CVB3 236 
variants. However, despite numerous attempts, we did not succeed to select such vari-237 
ants, indicating a high barrier to resistance of T-705. In contrast to the CHIKV RdRp, the 238 
CVB3 RdRp did not tolerate this mutation without the presence of the compensatory 239 
A239G amino acid substitution in motif A of the RdRp. Interestingly, a CVB3 variant car-240 
rying the single A239G mutation was previously reported to be a low fidelity polymer-241 
ase variant (13). Of all CVB3 infectious clones carrying any possible amino acid substitu-242 
tion at position 159, only the K159M variant proved to be viable and this only after the 243 
A239G mutation had also been acquired. Interestingly, in vitro polymerase assays re-244 
vealed that the K159R and K159M mutants exhibit crippled polymerase activity, which 245 
can be efficiently restored by the compensatory A239G substitution. As mentioned be-246 
fore, the Lys159 residue is located in Motif F of the RdRp, which has been reported to 247 
play an important role in NTP binding during viral RNA synthesis (10). NTP binding is 248 
known to be a major fidelity checkpoint and point mutations in this motif could anhilate 249 
polymerase activity or slow down catalysis (18). Mutating this lysine residue to an argi-250 
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nine or methionine resulted in reduced polymerization efficiency which is likely the 251 
consequence of less efficient access of the incoming NTPs to the active site of RdRp. Ac-252 
cording to previous reports (19, 20), the residue Ala239 participate in a tetrahedral hy-253 
drogen bond network. This network helps position the Asp238 residue to the active site 254 
of the RdRp, providing a direct link between the properly positioned NTP and a set of 255 
structural interactions that promote catalysis by stabilizing the closed active site (18). 256 
Based on structural analysis of CVB3 polymerase, the residues Lys159 and Ala239 are 257 
closely located in the channel of the incoming NTP. This channel becomes narrow when 258 
the Lys159 is mutated to a slightly bulkier R or M which is expected to impede access of 259 
the incoming NTP to the RdRp active site. With the “removal” of the methyl side-chain, 260 
the compensatory mutation A239G, appears to restore the access to the NTP channel. 261 
Consequently, the overall polymerase activity and the ability of the virus carrying this 262 
compensatory mutation to replicate in vitro is restored.  These data indicate first of all 263 
that the K159 residue is of key importance for the catalytic activity of the CVB3 RdRp 264 
and secondly that the residue at position 239 has an important role in its stability. Sur-265 
prisingly, the K159R-A239G and K159M-A239G variants proved respectively 3.5- and 2-266 
fold more sensitive (instead of resistant) to the antiviral activity of T-705 when com-267 
pared to WT. In contrast, no significant differences in sensitivity to ribavirin and rupin-268 
trivir were observed, indicating that the K159 residue is specifically involved in the mo-269 
lecular mechanism of action of T-705. Furthermore, also the low fidelity A239G variant 270 
was more sensitive to the antiviral effect of T-705, whereas the high fidelity variant 271 
A372V proved less sensitive. These data thus indicate that the fidelity of the viral RdRp 272 
is an important component in the susceptibility of the virus to T-705. Therefore, in vitro 273 
polymerase studies were performed to evaluate the fidelity of the K159 mutants. The 274 
K159R-A239G and K159M-A239G variants were respectively 1.7- and 6-fold more sensi-275 
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tive than the WT enzyme to the presence of an incorrect nucleotide and their fidelity 276 
was lower than that of the single A239G mutant. This provides an explanation for the 277 
increased sensitivity of the double mutants to the antiviral activity of T-705.  278 
To date, the precise mechanism that underlies the broad-spectrum anti-RNA virus activ-279 
ity of T-705 has not been completely unraveled. T-705 is converted intracellularly into 280 
its T-705-RTP form, which behaves as a pseudo-purine (21, 22). Consequently, incorpo-281 
ration of T-705-RTP into the viral RNA by the RdRp may possibly lead to chain termina-282 
tion or lethal mutagenesis. Some studies support lethal mutagenesis as the mechanism 283 
of action of T-705, for example against influenza virus (8) and norovirus (7). It was also 284 
reported that the incorporation of T-705-RTP by the norovirus RdRp does not result in 285 
complete chain termination (23). On the other hand, two studies have shown that in-286 
corporation of either a single (6) or two consecutive T-705-RTP molecules (24) into the 287 
nascent influenza viral RNA strand prevents further RNA strand extension. Moreover, 288 
we demonstrated earlier that the reduction of CHIKV RNA titers by T-705 correlates 289 
well with a decrease in infectivity, suggesting that lethal mutagenesis is probably not 290 
the mechanism of the antiviral effect of T-705 against CHIKV (9). By deep sequencing, 291 
we here determined the mutation frequency in the genome of CVB3 that had been cul-292 
tured in the presence of T-705. Indeed, the mutation frequency in presence of ribavirin 293 
was increased for all transition mutations; while T-705 had little effect on A->G and U-294 
>C transitions, but significantly increased C->U and G->A mutations between 3- and 10-295 
fold.  296 
In a previous study, low RdRP fidelity variants of CVB3, such as the A239G variant, were 297 
shown to be attenuated in immune-competent mice (13). Therefore, the fitness of the 298 
reverse-engineered K159 mutants was studied in immune-competent SJL mice. The 299 
A239G variant was included in the study as a positive control for in vivo attenuation. 300 
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Interestingly, the K159R-A239G variant had significantly lower viral RNA levels in se-301 
rum and sampled organs, and failed to efficiently infect the heart. In contrast, the infec-302 
tivity of the K159M-A239G variant was comparable to that of WT. However, sequencing 303 
of the collected samples revealed that the K159M-A239G variant completely reverted to 304 
WT in infected mice, providing an explanation for the above observation. 305 
To conclude, the conserved lysine residue of the F1 RdRp motif was shown to be key for 306 
the antiviral activity of T-705 against both CHIKV and CVB3 and is most likely also a key 307 
element in the interaction of T-705 with the RdRp of other +ssRNA viruses. In addition, 308 
this lysine is crucial for the proper functioning of the RdRp which explains most likely 309 
the high barrier for antiviral resistance. Moreover, we demonstrate for the first time the 310 
role of RdRp fidelity in the mechanism of CVB3 sensitivity for T-705. These results pro-311 
vide more insights into the mechanism of the antiviral activity of T-705 and may help to 312 
design novel broad-spectrum +ssRNA virus inhibitors that target this particular region 313 
of the RdRp. 314 
15 
MATERIALS AND METHODS 315 
Cells, viruses and inhibitors 316 
Vero A cells (ATCC CCL-81) and HeLa Rh cells [kindly provided by K. Andries, Janssen 317 
Infectious Diseases, Belgium]were maintained in minimal essential medium (MEM Rega-318 
3, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco), 1% L-glutamine (Gib-319 
co) and 1% sodium bicarbonate (Gibco). Virus propagation and antiviral assays were 320 
performed in the same medium but supplemented with 2% instead of 10% FBS. All cell 321 
cultures were maintained at 37°C in an atmosphere of 5% CO2 and 95%-99% relative 322 
humidity. 323 
T-705 was purchased from BOC Sciences (USA). Ribavirin (Virazole) was purchased 324 
from Valeant Pharmaceuticals International (Costa Mesa, CA). Rupintrivir was pur-325 
chased from Axon Medchem (The Netherlands). Compounds were dissolved in DMSO to 326 
yield 10 mg/ml stock solutions and were stored at 4°C until used. 327 
The CVB3 Nancy infectious cDNA clone was kindly provided by prof. F. van Kuppeveld, 328 
[University of Utrecht, The Netherlands]. 329 
Generation of CVB3 mutants 330 
A full set of CVB3 mutants at position 159 of the RdRp gene were constructed by intro-331 
ducing the desired mutation in the CVB3 Nancy infectious cDNA clone or in the CVB3 332 
RdRp-pASK3 plasmid in case of prokaryotic protein expression using the QuikChange 333 
mutagenesis kit (Agilent) and the primers described in Table 4. The identity of the mu-334 
tation in each of the constructs was verified by Sanger sequencing using the BigDye® 335 
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and a 3130 Genetic Analyzer 336 
automatic sequencer (Applied Biosystems). Subsequently, the mutated CVB3 infectious 337 
clones were in vitro transcribed into RNA using the RiboMAX™ Large Scale RNA Produc-338 
tion System-T7 (Promega). An appropriate amount of in vitro transcribed RNA was 339 
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transfected into Vero A cells using the DMRIE-C reagent (Invitrogen). Following incuba-340 
tion for 3 days at 37°C, the cultures were inspected for cytopathic effects (CPE). The cul-341 
tures with clear CPE were used to prepare virus stocks and stored at -80°C. From the 342 
cultures for which no CPE could be detected, the cells were harvested using Cells-to-343 
cDNA™ lysis buffer (Life Technologies) for extraction of intracellular RNA and quantita-344 
tive RT-PCR was performed to detect the presence of any replicating virus. In the case 345 
no viral RNA could be detected, the transfection procedure was repeated once more. A 346 
virus variant was considered ‘not viable’ when this second round also did not yield a 347 
positive PCR signal. 348 
Sanger Sequencing 349 
To confirm the presence of the introduced mutation in the reverse-engineered viruses, 350 
viral RNA was extracted using the NucleoSpin® RNA isolation kit (Macherey-Nagel). 351 
This RNA was used to generate five cDNA fragments that represent the entire coding 352 
region by RT–PCR amplification using the OneStep RT-PCR kit (Qiagen). These frag-353 
ments were purified using the Wizard® SV Gel and PCR Clean-Up System (Promega), 354 
and sequenced on both strands (BigDye® Terminator v3.1 Cycle Sequencing kit). The 355 
complete nucleotide sequences were assembled in Contig Express (VNTI, Invitrogen) 356 
and the genomes of the different variants were compared to the wild-type genome.  357 
Quantitative RT-PCR  358 
One-step quantitative RT-PCR was performed using the ABI 7500 Fast Real-Time PCR 359 
System (Applied Biosystems, USA). The sequences of primers and probe and the thermal 360 
cycling conditions used in qRT-PCR were as described before (25). The RNA copy num-361 
ber in each sample was determined by a standard curve using serial dilutions of CVB3 362 
standard cDNA included in the run.   363 
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Protein expression and purification 364 
The CVB3 RdRp-pASK3 plasmid used in this study is a bacterial expression vector, which 365 
does not use bacteriophage T7 RNA polymerase. It was generated by cloning the region 366 
encoding CVB3 RdRp from the CVB3 Nancy infectious cDNA clone into the prokaryote 367 
expression vector pASK3 (IBA) by PCR using two primers (forward 5’-368 
GGAATTCTAAGGAGGTAGAACCATGGGTGAAATAGAATTTATTGAGAGC-3’; reverse 5’-369 
CCGCCGCTCGAGTTAATGGTGATGGTGATGGTGAAAGGAGTCCAACCACTTCCTG-3’). The 370 
CBV3 RdRp contains a 6-histidine tag in the C-terminal end.  371 
E. coli strain Rosetta 2 cells (Novagen), transformed with the CVB3 RdRp-pASK3 WT or 372 
variant plasmids, were grown in LB medium at 37°C and induced overnight with 200 373 
µg/L anhydrotetracycline when the OD600 (optical density) value reached 0.6. Expres-374 
sion was performed at 17°C for 16h in light-protected conditions. Soluble fraction and 375 
metal–ion affinity chromatography (IMAC) purification step were performed as de-376 
scribed previously (26). The pure fractions analyzed on the SDS-PAGE gel were pooled, 377 
dialyzed into 20 mM Tris pH 9, 300 mM NaCl, 5% glycerol and 0.5 mM Tris (2-378 
carboxyethyl) phosphine hydrochloride (TCEP-HCl, Sigma) and concentrated using Cen-379 
tricon (Millipore) concentrators (30 kDa molecular weight cutoff). All proteins were 380 
stored at -20°C in cryoprotecting conditions using 50% glycerol.  381 
In vitro polymerase assays 382 
RNA oligo (dT) primers of 15 nucleotides (nt) and poly(rA) templates of approximately 383 
357nt in length were used for elongation assays in an analogous system as previously 384 
described (27, 28). Primers and templates were purchased from Thermo Fisher Scien-385 
tific and Amersham Pharmacia Biotech, respectively. Both were mixed for annealing at a 386 
molar ratio of 1:2 (template/primer) in the presence of water. The mixtures were incu-387 
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bated at 70°C during 10 min and cooled down slowly to room temperature and then left 388 
stored at -20°C until further use.  389 
In vitro enzymatic assays were carried out using polymerase assay buffer (20 mM Hepes 390 
pH 7.5; 50 mM KCl; 5 mM DTT; 5 mM MgCl2) mixed with 1 μM CVB3 RdRp and 0.5 μM 391 
pre-annealed primer-template substrate in 10 μL of reaction. Thus, the polymerase and 392 
its RNA substrate were assembled at 30°C for 15 min to perform an active elongation 393 
complex. The primer extension was started by the addition of a mixture of 3 μCi [α-32P]-394 
UTP and 10 μM of UTP unlabeled using the same polymerase assay buffer in an equal 395 
volume of reaction. In the case of competition assays, CTP was added at concentrations 396 
of 1, 2, 3, 4, or 5 mM for WT and A239G variants. In the case of K159R-A239G and 397 
K159M-A239G variants, concentrations were adjusted to 0.1, 0.25, 0.5, 1, or 2 mM of 398 
CTP. NTPs were purchased from GE Healthcare. 399 
After incubation at 30°C, aliquots of reactions were quenched at various time points by 400 
the addition of an equal volume of loading buffer (formamide with 10 mM EDTA). Reac-401 
tion products were analyzed by PAGE using polyacrylamide sequencing gels of 14% 402 
acrylamide:bisacrilamide (19:1), 7 M urea with TTE buffer (89 mM Tris pH 8.0, 28 mM 403 
taurine (2-aminoethanesulfonic acid), 0.5 mM EDTA). RNA bands were visualized using 404 
a Fluorescent Image Analyzer FLA3000 (Fuji), and quantified using Image Quant Soft-405 
ware (Fuji).  406 
CPE reduction assay 407 
HeLa Rh cells were seeded in 96-well tissue culture plates (BD Falcon) at a density of 1.8 408 
×104 cells/well and were allowed to adhere overnight. The next day, 2-fold dilution se-409 
ries of T-705, ribavirin or rupintrivir (starting concentration 637, 819 and 8 µM, respec-410 
tively) were added to the cultures that were then infected with the selected CVB3 vari-411 
ant at a final multiplicity of infection (MOI) of 0.001 PFU/cell. At day 3 post-infection 412 
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(p.i.), the antiviral effect was quantified using the MTS/PMS method as described by the 413 
manufacturer (Promega, The Netherlands). The 50% effective concentration (EC50), 414 
which is defined as the concentration of compound that is required to inhibit virus-415 
induced cell death by 50%, was determined using logarithmic interpolation. 416 
Genetic stability of the generated mutants  417 
To assess the genetic stability of the reverse-engineered mutations, HeLa Rh cells were 418 
seeded at a density of 4x104 cells/well in 48-well plates and infected with the selected 419 
CVB3 variant at a MOI=0.01. Each variant was passaged 3 times after which the appro-420 
priate region of the RdRp was sequenced. 421 
Virus phenotyping  422 
Vero A cells were seeded in 6-well plates (BD Falcon) at a density of 1×106 cells/well. 423 
Following 24h of incubation, cells were washed with PBS and then infected with 10-fold 424 
serial dilutions of the respective virus stock. After 2h of incubation with gentle shaking, 425 
the monolayers were washed with PBS after which a freshly prepared 1:1 mixture of 426 
liquefied 1% low melting point agarose (Invitrogen) and 2x medium with 4% FBS was 427 
added. On day 3 p.i., the monolayers were carefully washed with PBS, fixed with 4% 428 
formaldehyde and stained with Giemsa solution to visualize the virus-induced plaques, 429 
after which they were counted to calculate the number of plaque forming units (pfu) per 430 
mL.  431 
In parallel, the growth kinetics of different CVB3 mutants were determined by infecting 432 
Vero A cells (5×104 cells/well) in 96-well plates with the respective virus variants at a 433 
MOI of 3. After 1h of infection, the cells were washed with assay medium to remove non-434 
adsorbed virus. At 4, 6, 8, 10, 12 and 24h p.i., the culture supernatant was collected, after 435 
which the infectious virus content was quantified by plaque assay as before. 436 
The effect of T-705 on the mutation frequency of CVB3 by deep sequencing 437 
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HeLa Rh cells were seeded in a 48-well plate at a cell density of 4×104 cells/well and 438 
were left to adhere overnight. Next day, cells were treated with T-705 or ribavirin at a 439 
final concentration that equals the EC50 value against the tested variant. Cells were then 440 
infected with CVB3 WT, A239G or A372V at a final MOI=0.001. On day 3 p.i., the culture 441 
supernatant in each well was collected and the virus populations in these samples were 442 
subjected to a deep sequencing study. Samples were RNA extracted using Trizol and RT-443 
PCR amplified by RT (Superscript III) and PCR (Phusion) using primers sets that covered 444 
the whole genome in 3-4 kb fragments. PCR fragments were purified via the Nucleospin 445 
Gel and PCR Clean-up kit (Macherey-Nagel). PCR products were then fragmented 446 
(Fragmentase), linked to Illumina multiplex adapters, clustered and sequenced with 447 
NextSeq500 technology. Sequences were demultiplexed by CASAVA with no mismatches 448 
permitted. Clipping was performed using the fastq-mcf tool 449 
(http://code.google.com/p/ea-utils/wiki/FastqMcf), removing common adapter con-450 
taminants and trimming low quality bases (Phred<30). Clipped reads were aligned to 451 
the CVB3 Nancy sequence as reference with a maximum of 2 mismatches per read, and 452 
no gaps, using BWA v0.5.9. Alignments were processed using SAMTools to obtain a pile-453 
up of the called bases at each position. The ViVAn pipeline was used to identify statisti-454 
cally significant variants above the background noise due to sequencing error, in every 455 
sufficiently covered site (>1000X) (29). Briefly, for each position throughout the viral 456 
genome, base identity and their quality scores were gathered. Each variant was deter-457 
mined to be true using a generalized likelihood-ratio test and its allele rate was modified 458 
according to its covering read qualities based on a maximum likelihood estimation. Ad-459 
ditionally, a confidence interval was calculated for each allele rate. To correct for multi-460 
ple testing, Benjamini-Hochberg false-discovery rate of 5% was set. The frequency of 461 
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transition mutations for compound-treated samples was determined at each position 462 
across the genome and compared to untreated controls in a two-tailed paired t-test.  463 
In vivo experiments 464 
SJL mice were bred in the Experimental Animal Breeding Facility of the University of 465 
Leuven, Belgium. Four groups of SJL mice (5 animals/group) were used. Mice were in-466 
fected with 105 PFU of the selected CVB3 variant (WT, K159R-A239G, K159M-A239G or 467 
A239G) by i.p. injection (200 µl). On day 3 p.i., all animals were euthanized and serum, 468 
heart, spleen and pancreas were collected. The viral RNA was isolated from serum using 469 
the NucleoSpin® RNA isolation kit (Macherey-Nagel) and from the homogenized organs 470 
using the RNeasy Mini Kit (Qiagen). The amount of viral RNA in serum and organs was 471 
then quantified by qRT-PCR as described before. In addition, the number of infectious 472 
virus particles in the heart was determined by end-point titration in Vero A cells. 473 
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Figure legends  582 
Figure 1. Multiple sequence alignment of Motif F1 of viral RdRp. Part of the multiple 583 
sequence alignment of RdRp of chikungunya virus (ACY09947.1), enteroviruses [Cox-584 
sacikevirus A21 (ABM54541.1), Coxsackievirus B3 (AAA74400.1), poliovirus type 1 585 
(AAP37265.1), enterovirus D68 (AAR98503.1) and human rhinovirus B14 586 
(NP_740525.1)], flaviviruses [Zika virus (AMO03410.1), Japanese encephalitis virus 587 
(ABU94628.1)], murine norovirus (AEY83582.1) and hepatitis C virus (CAB46913.1) 588 
that was generated using the PROMALS server 589 
(http://prodata.swmed.edu/promals/promals.php). Motif F1 of the RdRp is indicated by 590 
a black box and the residues corresponding to K291 in CHIKV are highlighted in yellow. 591 
Figure 2. Coxsackievirus B3 polymerase structure. A) Structure of CVB3 polymerase 592 
(PDB id: 4K4Y) showing the locations of Lys159 (K159) and Ala239 (A239) highlighted 593 
in blue and magenta, respectively. B) Model of CVB3 polymerase structure (fingers = 594 
blue, palm = green, thumb = red ribbons) with favipiravir triphosphate (T-705-RTP). 595 
The primer RNA strand has a yellow ribbon, the template has a brown ribbon. T-705-596 
RTP has purple carbons. The complementary G is in cyan. The carbons of K159 and 597 
A239 residues are highlighted in green. CVB3 hydrogen bonds from the sugar part of T-598 
705-RTP to the N-terminus (in cyan) via A239 (green carbons) are shown as black 599 
dashed lines. 600 
Figure 3. Coxsackievirus B3 RdRp variants exhibit distinct polymerase activities. 601 
RNA polymerase assays were performed as described in the Methods section. A) dT15-602 
poly(rA) is an homopolymeric primer:template allowing the incorporation of [α-32P]-603 
UMP or UMP at the dT primer 3’-end. B) RNA products of a representative PAGE are 604 
shown after at 2, 5 and 10 min of quenching. C) Quantified RNA products shown are 605 
mean values ± SD of 2 independent experiments. Statistical analysis was performed 606 
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using two-way ANOVA in reference to WT for K159R or K159M (*p<0.05) ; to K159R for 607 
K159R-A239G (*p<0.05) ; or to K159M for K159M-A239G (*p<0.05). 608 
Figure 4. Top view of the RdRp from CVB3 (PDB code 3CDW). A) The locations of the 609 
residues K159 and A239 are highlighted in purple and red, respectively. The channel 610 
from incoming rNTPs is shown between these residues.  B) The long chain of the argi-611 
nine residue, R159 mutant, is highlighted in purple narrowing the channel for incoming 612 
rNTPs.  A239 is shown in red. C) The mutant G239, in red, is able to reestablish the ac-613 
cess of rNTPs in the channel. The residue R159 is shown in purple. D-F) representative 614 
zoom of A to C, respectively. 615 
Figure 5. Phenotype of reverse-engineered CVB3 variants. A) Plaque phenotypes of 616 
different CVB3 variants were determined by infecting Vero A cells with a 10-fold serial 617 
dilution of each variant followed by addition of an agarose overlay. After 3 days, viral 618 
plaques were visualized by Giemsa staining. A representative image with spread plaques 619 
is shown. B) Growth curves were generated by infecting Vero A cells with the selected 620 
CVB3 variant at a MOI of 3, after which the infectious virus titer in the medium was de-621 
termined at various time points after infection by plaque assay. Infectious virus titer 622 
values are the mean ± SD of 2 independent experiments. Significant differences with re-623 
spect to WT (*p<0.05 or ***p<0.001) were analyzed by two-way ANOVA. C) The sensi-624 
tivity of the reverse-engineered CVB3 variants to the antiviral effect of T-705 was as-625 
sessed in HeLa Rh cells by a CPE reduction assay. Cell viability was measured using the 626 
MTS/PMS method. Data are expressed as percentages of untreated controls and are 627 
mean values ± SD of at least 3 independent experiments. 628 
Figure 6. Chemical structure of favipiravir, ribavirin and rupintrivir 629 
Figure 7. K159R-A239G and K159M-A239G are low-fidelity RdRp variants. Compe-630 
tition assays were performed with 3 μCi [α-32P]-UTP/cold 10 μM UTP  challenged with 631 
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CTP concentrations of 1, 2, 3, 4, 5 mM for (B) the wild-type and (C) A239G, or 0.1, 0.25, 632 
0.5, 1, 2 mM for (D) K159R-A239G and (E) K159M-A239G variants. The total RNA prod-633 
ucts formed represents a mean ± SD of 2 independent experiments and was measured as 634 
a dose-response curve with at least one data point above and below 50% RNA product 635 
formed (A) to be able to calculate an interpolated apparent IC50 value. Data were fit 636 
(Figure 3F) and statistical analysis were performed using two-way ANOVA in reference 637 
to WT for K159R-A239G (*p<0.05) and for K159M-A239G (**p<0.01). 638 
Figure 8. T-705 significantly increases the mutation frequency of CVB3. Wild-type 639 
(A), high-fidelity A372V (B) and low-fidelity A239G (C) viruses were either mock-640 
treated (open bars) or treated with T-705 (light grey bars) or ribavirin (dark grey bars), 641 
at concentrations equal to the corresponding EC50, and subjected to whole-genome deep 642 
sequencing. The frequency of transition mutations occurring at each A, C, G, U was calcu-643 
lated and used to determine the mean frequency and SEM. *p<0.05, **p<0.01, 644 
***p=0.0006, ****p<0.0001; two-tailed paired t-test; n=1416 (A->G), n=1169 (C->U); 645 
n=988 (G->A); n=1182 (U->C). 646 
Figure 9. In vivo fitness of CVB3-K159 variants in SJL mice. SJL mice were infected 647 
with 105 PFU of CVB3 WT, A239G, K159R-A239G or K159R-A239G variants (n=5 per 648 
variant). On day 3 post infection, all mice were euthanized after which serum and select-649 
ed organs were collected for RNA extraction. The amount of viral RNA in A) serum, B) 650 
heart, C) pancreas and D) spleen was determined by qRT-PCR. The number of infectious 651 
virus particles in the heart (E) was determined by end-point titration (*p<0.05 and 652 
**p<0.01, Kruskal-Wallis test). 653 
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Table 1. Mutation analysis of amino acid 159 of the CVB3 RdRp 655 





Vero A HeLa Rh 
Lys (wild-type) Viable - 2.2E+07 1.4E+05 
Arg Viable, but with A239G 6.5E+06 1.9E+05 
Met Viable, but with A239G 7.9E+07 2.5E+06 
Asp Reverted to WT - - - 
Asn Reverted to WT - - - 
Gln Reverted to WT - - - 
Ser Reverted to WT - - - 
Thr Reverted to WT - - - 
His Reverted to WT - - - 
Phe Reverted to WT - - - 
Val Reverted to WT - - - 
Ala Not viable - - - 
Ile Not viable - - - 
Leu Not viable - - - 
Trp Not viable - - - 
Tyr Not viable - - - 
Glu Not viable - - - 
Cys Not viable - - - 
Gly Not viable - - - 
Pro Not viable - - - 
*The phenotype indicates whether the transfected CVB3 variant with the desired mutation 656 
was viable, reverted to WT, or did not yield viable virus. Each transfection was performed 657 
at least in duplicate.  658 
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Table 2. Genetic stability of the reverse-engineered CVB3 variants in cell culture 659 
Engineered genotype 
Genetic stability after 3 passages 
Status* Genotype 
A372V Stable V372 
A239G Stable G239 
K159R-A239G Partially stable K159-G239 
K159M-A239G Partially stable K159-G239 
*The status indicates whether the mutations were stable, partially stable or reverted back 660 
to WT over three passages in HeLa Rh cells.  661 
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Table 3. Antiviral activity of different classes of compounds against CVB3-K159 662 
variants 663 
CVB3 variant 
EC50 ± SD in µM (Fold of resistance) 
T-705 Ribavirin Rupintrivir 
WT 229 ± 24 254 ± 37 0.6 ± 0.1 
K159R-A239G 67 ± 6 (0.3)**** 261 ± 23 1 ± 0.4 
K159M-A239G 116 ± 14 (0.5)*** 198 ± 9 0.7 ± 0.1 
A239G 108 ± 2 (0.5) **** 164 ± 10 (0.6)** 0.8 ± 0.02 
A372V 458 ± 27 (2) **** 419 ± 16 (1.6)**** 0.8 ± 0.01 
 664 
The values between brackets represent the fold of resistance (EC50 mutant/EC50 WT), 665 
which have significant p-values (** p< 0.01, *** p< 0.001, **** p< 0.0001, Student T-666 
test).The 50% cytotoxic/cytostatic concentrations (CC50) for T-705, ribavirin and rupin-667 
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Table 4. CVB3 site-directed mutagenesis primers 674 
Mutation Primer Sequence (5’–3’) Length Position  Tm 
A239G MFAT1 ttactctgggtacgatggtagcttaagccctgtctg 39 719 73.7
MRAT1 cagacagggcttaagctaccatcgtacccagagtaa 39 719 73.7
A372V MFAT2 gttacctggaccaacgtcactttcctaaagagg 33 1118 69.5
MRAT2 cctctttaggaaagtgacgttggtccaggtaac 33 1118 69.5
K159R MFAT3 ggtgacttatgtaagagatgagctcaggtc 30 479 66.8
MRAT3 gacctgagctcatctcttacataagtcacc 30 479 66.8
K159M MFAT4 ggtgacttatgtaatggatgagctcaggtc 30 479 66.8
MRAT4 gacctgagctcatccattacataagtcacc 30 479 66.8
 675 
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